Global epidemiology and antimicrobial resistance of extended-spectrum β-lactamase-producing Vibrio species: A One Health systematic review and meta-analysis.
4 affiliations
- 1Department of Microbiology, Faculty of Public Health, Mahidol University, Bangkok 10400, Thailand.
- 2Department of Veterinary Public Health, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330, Thailand.
- 3Department of Agricultural and Fishery Science, Faculty of Science and Technology, Prince of Songkla University, Pattani 94000, Thailand.
- 4Research Unit in Microbial Food Safety and Antimicrobial Resistance, Department of Veterinary Public Health, Faculty of Veterinary Science, Chulalongkorn University, Bangkok 10330, Thailand.
Abstract
Background and aim
Vibrio spp. are important aquatic bacteria associated with human disease, aquaculture losses, seafood safety, and environmental reservoirs of antimicrobial resistance (AMR). The emergence of extended-spectrum β-lactamase (ESBL)-producing Vibrio spp. may compromise β-lactam therapy and facilitate resistance dissemination across interconnected One Health sectors. This systematic review and meta-analysis aimed to determine the prevalence of Vibrio spp. and ESBL-producing isolates and characterize their phenotypic AMR, multidrug resistance (MDR), and resistance-associated genes across human, animal, and environmental sources.Materials and methods
Literature published from 2012 to 2024 was systematically retrieved from PubMed, Scopus, and Google Scholar following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The protocol was registered in the International Prospective Register of Systematic Reviews (CRD420251114318). Pooled prevalence estimates were calculated using random-effects models, heterogeneity was assessed using Cochran's Q and I² statistics, and subgroup analyses were conducted by continent and Vibrio species. Risk-of-bias was evaluated using the Joanna Briggs Institute checklist.Results
Of 1,120 records identified, 31 studies were included, representing 4,486 samples and 3,242 Vibrio isolates, predominantly from Asia and Africa. The pooled prevalence of Vibrio spp. was 48.3% (95% confidence interval [CI]: 34.0-62.7%; I² = 99.37%), whereas ESBL-producing Vibrio spp. had a pooled prevalence of 19.4% (95% CI: 3.2-43.7%; I² = 95.87%). Ampicillin showed the highest pooled β-lactam resistance at 73.6% (95% CI: 58.4-86.4%). The overall pooled MDR prevalence was 31.5% (95% CI: 6.1-64.7%). Resistance varied substantially among Vibrio species, including marked resistance to third-generation cephalosporins in selected species. Among resistance determinants, bla TEM was predominant, with a pooled prevalence of 33.8%, while carbapenemase-associated bla VIM and bla IMP were also detected. Considerable between-study heterogeneity was observed for most outcomes.Conclusion
ESBL-producing and multidrug-resistant Vibrio spp. occur across human, animal, and environmental sources, demonstrating substantial geographical and species-specific variation. The high β-lactam resistance and detection of clinically important resistance determinants emphasize the need for harmonized antimicrobial susceptibility testing, molecular surveillance, and integrated One Health monitoring to limit the emergence and dissemination of resistant Vibrio spp.
Related
- Effects of a community-based intervention bundle on household transmission of extended spectrum β-lactamase-producing Escherichia coli in rural Burkina Faso to target community-level drivers of antimicrobial resistance in sub-Saharan Africa: a cluster-randomised trial
- Schistosoma-Salmonella co-infection in Africa: Epidemiology, biological mechanisms, and antimicrobial resistance: A systematic review and meta analysis
- Antimicrobial Usage and Presence of Extended-Spectrum β-Lactamase-Producing Enterobacterales in Healthy Chickens From Farms in Grand-Abidjan and Korhogo, Côte d'Ivoire.
- Genomic analysis and antimicrobial resistance profiling of Klebsiella pneumoniae clinical isolates from urinary tract infections in India: prevalence of class A β-lactamase with molecular docking and simulation insights.
- Bloodstream Infections in Patients with Malignancy: Microbiological Epidemiology, Antimicrobial Resistance, and Factors Associated with Mortality in a Nine-Year Single-Center Retrospective Cohort
BibTeX
@article{thaotumpitak2026global,
title = {{Global epidemiology and antimicrobial resistance of extended-spectrum β-lactamase-producing Vibrio species: A One Health systematic review and meta-analysis.}},
author = {Varangkana Thaotumpitak and Saran Anuntawirun and Nawaphorn Roongrojmongkhon and Manoj Tukaram Kamble and Saharuetai Jeamsripong},
journal = {Veterinary world},
year = {2026},
month = sep,
doi = {10.14202/vetworld.2026.4210-4229},
url = {https://europepmc.org/article/MED/42928720},
note = {CC BY},
}
RIS
TY - JOUR
TI - Global epidemiology and antimicrobial resistance of extended-spectrum β-lactamase-producing Vibrio species: A One Health systematic review and meta-analysis.
AU - Varangkana Thaotumpitak
AU - Saran Anuntawirun
AU - Nawaphorn Roongrojmongkhon
AU - Manoj Tukaram Kamble
AU - Saharuetai Jeamsripong
PY - 2026
DA - 2026/09/22
JO - Veterinary world
DO - 10.14202/vetworld.2026.4210-4229
UR - https://europepmc.org/article/MED/42928720
AB - Background and aim Vibrio spp. are important aquatic bacteria associated with human disease, aquaculture losses, seafood safety, and environmental reservoirs of antimicrobial resistance (AMR). The emergence of extended-spectrum β-lactamase (ESBL)-producing Vibrio spp. may compromise β-lactam therapy and facilitate resistance dissemination across interconnected One Health sectors. This systematic review and meta-analysis aimed to determine the prevalence of Vibrio spp. and ESBL-producing isolates and characterize their phenotypic AMR, multidrug resistance (MDR), and resistance-associated genes across human, animal, and environmental sources.Materials and methods Literature published from 2012 to 2024 was systematically retrieved from PubMed, Scopus, and Google Scholar following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The protocol was registered in the International Prospective Register of Systematic Reviews (CRD420251114318). Pooled prevalence estimates were calculated using random-effects models, heterogeneity was assessed using Cochran's Q and I² statistics, and subgroup analyses were conducted by continent and Vibrio species. Risk-of-bias was evaluated using the Joanna Briggs Institute checklist.Results Of 1,120 records identified, 31 studies were included, representing 4,486 samples and 3,242 Vibrio isolates, predominantly from Asia and Africa. The pooled prevalence of Vibrio spp. was 48.3% (95% confidence interval [CI]: 34.0-62.7%; I² = 99.37%), whereas ESBL-producing Vibrio spp. had a pooled prevalence of 19.4% (95% CI: 3.2-43.7%; I² = 95.87%). Ampicillin showed the highest pooled β-lactam resistance at 73.6% (95% CI: 58.4-86.4%). The overall pooled MDR prevalence was 31.5% (95% CI: 6.1-64.7%). Resistance varied substantially among Vibrio species, including marked resistance to third-generation cephalosporins in selected species. Among resistance determinants, bla TEM was predominant, with a pooled prevalence of 33.8%, while carbapenemase-associated bla VIM and bla IMP were also detected. Considerable between-study heterogeneity was observed for most outcomes.Conclusion ESBL-producing and multidrug-resistant Vibrio spp. occur across human, animal, and environmental sources, demonstrating substantial geographical and species-specific variation. The high β-lactam resistance and detection of clinically important resistance determinants emphasize the need for harmonized antimicrobial susceptibility testing, molecular surveillance, and integrated One Health monitoring to limit the emergence and dissemination of resistant Vibrio spp.
SN - 0972-8988
SN - 2231-0916
ER -